# Stephen V. Liu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/stephen-v-liu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,078 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 57 |
| i10-index | 201 |
| Last Known Institution | Georgetown University |
| OpenAlex ID | https://openalex.org/A5043871151 |
| ORCID iD | 0000-0002-4852-3914 |
| Works | 842 |

## Researcher papers

- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-patients-with-advanced-or-metastatic-ntrk-fusion-positive-solid/)
- [Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)](https://scholariq.org/papers/updated-overall-survival-and-pd-l1-subgroup-analysis-of-patients-with-extensive/)
- [Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)](https://scholariq.org/papers/safety-and-antitumor-activity-of-the-multitargeted-pan-trk-ros1-and-alk/)
- [Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study](https://scholariq.org/papers/pembrolizumab-for-platinum-and-cetuximab-refractory-head-and-neck-cancer-results/)
- [COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study](https://scholariq.org/papers/covid-19-in-patients-with-thoracic-malignancies-teravolt-first-results-of-an/)
- [Emerging Epidemic of Hepatitis C Virus Infections Among Young Nonurban Persons Who Inject Drugs in the United States, 2006–2012](https://scholariq.org/papers/emerging-epidemic-of-hepatitis-c-virus-infections-among-young-nonurban-persons/)
- [Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study](https://scholariq.org/papers/pralsetinib-for-ret-fusion-positive-non-small-cell-lung-cancer-arrow-a-multi/)
- [Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study](https://scholariq.org/papers/pembrolizumab-in-patients-with-thymic-carcinoma-a-single-arm-single-centre-phase/)
- [Refining the treatment of NSCLC according to histological and molecular subtypes](https://scholariq.org/papers/refining-the-treatment-of-nsclc-according-to-histological-and-molecular-subtypes/)
- [Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study](https://scholariq.org/papers/correlation-between-treatments-and-outcomes-of-patients-with-egfr-mutated-non/)
- [SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer](https://scholariq.org/papers/sez6-expression-and-lineage-plasticity-in-small-cell-lung-cancer-and-transformed/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Georgetown University](https://scholariq.org/institutions/georgetown-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.